Idelalisib in second-line treatment for CLL: Added benefit again not proven

(Institute for Quality and Efficiency in Health Care) Since the first G-BA decision was time-limited, a new assessment was required -- under changed circumstances: Following severe complications, the therapeutic indication had been restricted.